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Abstract
The mitotic spindle assembly checkpoint (SAC) maintains genome
stability and marks an important target for antineoplastic thera-
pies. However, it has remained unclear how cells execute cell fate
decisions under conditions of SAC-induced mitotic arrest. Here, we
identify USP9X as the mitotic deubiquitinase of the X-linked inhi-
bitor of apoptosis protein (XIAP) and demonstrate that deubiquity-
lation and stabilization of XIAP by USP9X lead to increased
resistance toward mitotic spindle poisons. We find that primary
human aggressive B-cell lymphoma samples exhibit high USP9X
expression that correlate with XIAP overexpression. We show that
high USP9X/XIAP expression is associated with shorter event-free
survival in patients treated with spindle poison-containing
chemotherapy. Accordingly, aggressive B-cell lymphoma lines with
USP9X and associated XIAP overexpression exhibit increased
chemoresistance, reversed by specific inhibition of either USP9X or
XIAP. Moreover, knockdown of USP9X or XIAP significantly delays
lymphoma development and increases sensitivity to spindle
poisons in a murine El-Myc lymphoma model. Together, we specify
the USP9X–XIAP axis as a regulator of the mitotic cell fate decision
and propose that USP9X and XIAP are potential prognostic
biomarkers and therapeutic targets in aggressive B-cell lymphoma.
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Introduction
The spindle assembly checkpoint (SAC) is an important target in
cancer therapy, and microtubule poisons such as taxanes and vinca
alkaloids are widely used as highly effective chemotherapy agents
(Manchado et al, 2012). The failure of tumor cells to initiate apopto-
sis during the active checkpoint signal is a major factor that limits
the efficacy of antimitotic drugs (Janssen & Medema, 2011). There-
fore, the identification of factors that regulate mitotic survival is of
imminent relevance, both in generating a mechanistic understand-
ing of the SAC and for the identification of novel target structures in
cancer therapy.
Pathways of the ubiquitin proteasome system are critically
involved in SAC signaling, mediating both proteolysis-dependent
and proteolysis-independent mechanisms (Lara-Gonzalez et al,
2012). Indeed, the target of the SAC is CDC20, which activates the
anaphase-promoting complex/cyclosome (APC/C) that triggers
anaphase and mitotic exit by ubiquitylating securin and cyclin B1
(Lara-Gonzalez et al, 2012). Other ubiquitin ligases, particularly
members of the cullin ring ligase (CRL) family, regulate different
aspects of mitotic spindle formation, mitotic survival, and chromo-
some alignment, respectively (Bassermann et al, 2014). By contrast,
the role of deubiquitylases (DUBs) in mitotic control has remained
more elusive.
Inhibitor of apoptosis proteins (IAP) are key negative regulators
of cell death. Specific to the IAP member X-linked inhibitor of apop-
tosis protein (XIAP) is the ability to directly bind and inhibit acti-
vated caspases 3, 7, and 9 via its N-terminal baculoviral IAP repeat
domains (BIR) (Deveraux et al, 1997; Chai et al, 2001; Riedl et al,
2001; Shiozaki et al, 2003). Notably, XIAP exerts ubiquitin ligase
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activity and promotes ubiquitylation of substrates such as RIPK2,
but also regulates its own abundance via autoubiquitylation, an
important mechanism for maintaining XIAP homeostasis (Vaux &
Silke, 2005) (Damgaard et al, 2012). Increased expression of XIAP is
found in different cancers, including B-cell lymphomas; however,
the functional relevance has not been fully elucidated (Akyurek
et al, 2006).
Diffuse large B-cell lymphoma (DLBCL) is the most common
aggressive B-cell lymphoma in adults (Shaffer et al, 2012). The
majority of patients achieve a remission of their disease after first-
line immunochemotherapy, which typically includes vinca alkaloids
and checkpoint inducing agents such as anthracyclines, but 10% of
patients are upfront refractory. Notably, about one-third of initially
treatment-responsive tumors eventually recur or become refractory
to conventional therapy (Martelli et al, 2013), indicating the urgent
need to develop more specific targeted therapies. While a number of
risk factors for aggressive disease as well as adverse genetic profiles
and histologic categories have been defined (Ziepert et al, 2010;
Shaffer et al, 2012; Pasqualucci, 2013), the molecular mechanisms
of treatment resistance and escape from mitotic cell death remain
obscure.
In this study, we set out to investigate the role of DUBs in the
regulation of mitotic cell fate decisions. These studies revealed a
mitosis-specific function for the ubiquitin-specific protease 9X
(USP9X), which we show to deubiquitylate and stabilize XIAP in
order to promote mitotic survival. We demonstrate that loss of this
anti-apoptotic pathway sensitizes cells to spindle poison-induced
mitotic cell death independent of their MCL1 status and show that
overexpression of USP9X and concomitant high expression of XIAP
determine adverse prognosis and treatment resistance in human
aggressive B-cell lymphomas.
Results and Discussion
To begin assessing the role of deubiquitylation in mitotic control,
we analyzed cell cycle profiles of different USP family DUBs. This
approach identified a significant enrichment of USP9X in mitotic
cells (Fig 1A). USP9X is involved in fundamental processes such as
pre-implantation development and is considered to particularly
enhance cell survival by stabilizing different pro-survival substrates
such as b-catenin and the pro-survival BCL2 family member MCL1
(Taya et al, 1999; Murray et al, 2004; Sacco et al, 2010; Schwickart
et al, 2010; Vucic et al, 2011). While these pro-survival activities
have not been shown to occur in a cell cycle-dependent manner,
USP9X demonstrates mitotic activity as evidenced by its role in
regulating chromosome alignment and segregation by means of
targeting the inhibitor of apoptosis protein (IAP) family member
survivin and Aurora B to centromeres (Vong et al, 2005). However,
this mechanism coordinates proper chromosome division rather
than cell survival. We therefore reasoned that USP9X might exert
mitotic pro-survival activity by stabilizing other IAP family
members than survivin. To investigate this possibility, we analyzed
the stability of different IAP proteins under the condition of RNAi-
mediated USP9X knockdown. We found that XIAP was the only
candidate that displayed significant loss of mitotic expression in
USP9X-silenced cells that was restored upon treatment with the
proteasome inhibitor MG132, thus indicating a role for USP9X in
proteasome-dependent mitotic stabilization of XIAP (Fig 1B and
Appendix Fig S1A and B). In further support of this notion, we
found that both XIAP and USP9X display parallel accumulation in
mitosis (Fig 1A).
To further substantiate a role for USP9X in regulating XIAP in
mitosis, we tested direct interaction of USP9X and XIAP. Indeed, co-
immunoprecipitation studies under semi-endogenous conditions
identified preferential interaction of XIAP with USP9X in mitosis
(Fig 1C and Appendix Fig S1C). Likewise, immunofluorescence
studies revealed co-localization of USP9X and XIAP in either prome-
taphase or metaphase cells (Appendix Fig S1D). Moreover, the inter-
action of USP9X and XIAP increased upon prolonged exposure to
taxol, which leads to a gradual mitotic enrichment of cells
(Appendix Fig S1E). Direct interaction of USP9X with XIAP was
further verified in vitro using purified proteins (Fig EV1A). Notably,
XIAP specifically interacted with the USP9X fragment containing the
active cystein protease site (Fig EV1A).
Mapping studies using different deletion mutants narrowed the
USP9X binding motif to the BIR2 and BIR3 domains of XIAP (aa152–
323) (Fig EV1B). This sequence contains a glycine residue at posi-
tion 188, whose germline mutation marks a causative molecular
aberration of the X-linked lymphoproliferative syndrome type 2
(XLP-2), which features low or instable expression of XIAP and
premature apoptosis of lymphocytes in response to different stimuli
(Rigaud et al, 2006). Two respective mutations of XIAP at G188
have been described, G188E and G188R, which diminish XIAP
expression levels in patient B cells (Marsh et al, 2009; Gifford et al,
2014). Indeed, we found that both mutations abolish binding of
XIAP to USP9X, and both XIAP mutants demonstrate reduced stabil-
ity in mitosis (Figs 1D and EV1C). Moreover, SMAC mimetics,
which are known to interfere with protein binding of XIAP via its
BIR2 domain (Krieg et al, 2009; Damgaard et al, 2013), disrupted
the interaction of USP9X to XIAP (Fig EV1D). Together, these data
suggest a role of Gly188 within the BIR2 domain as the binding site
of XIAP for USP9X.
We next investigated whether mitotic stability of XIAP directly
relies on the deubiquitylating activity of USP9X. To this end, we
performed deubiquitylation assays using mitotic cells under condi-
tions of both USP9X knockdown and forced USP9X expression.
Indeed, ubiquitylation of XIAP was substantially increased upon
silencing or chemical inhibition of USP9X (Figs 1E and EV2A) in
mitotic cells, while forced expression of USP9X attenuated XIAP
ubiquitylation (Fig EV2A). In line with this, we found the overall
deubiquitylation activity of USP9X to be elevated in mitosis
(Fig EV2B). Notably, staining with linkage-specific ubiquitin anti-
bodies revealed that USP9X removes K48-linked ubiquitin chains
from XIAP (Fig EV2C). Moreover, we found that ubiquitylation of
the XIAPG188R mutant is substantially increased in mitotic cells as
compared to WT XIAP and that mitotic ubiquitylation of XIAPG188E
remained unaffected upon USP9X overexpression (Fig EV2D and E).
These findings support the notion that the reduced stability of these
mutants may result from their inability to bind USP9X with the
consequence of increased ubiquitylation and degradation, and may
have implications in the pathophysiology of the XLP-2 syndrome. In
a complimentary approach, we found that a catalytically inactive
USP9X mutant (USP9XC1556S) was unable to confer stability to XIAP
in mitotic cells (Fig 1F). Likewise, addition of the USP9X inhibitor
WP1130 destabilized XIAP in mitotic cells (Fig 1G).
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Figure 1. USP9X binds, deubiquitylates, and stabilizes XIAP in mitosis.
A Immunoblot analysis of HeLa cells using the indicated antibodies that were synchronized in G1/S phase using a double thymidine block or in mitosis using sequential
thymidine and nocodazole treatment and collected at the given time points.
B Immunoblot analysis of HeLa cells that were transfected with siRNA oligonucleotides as indicated and left untreated or synchronized in mitosis using sequential
thymidine and nocodazole treatment.
C Co-immunoprecipitation of XIAP and endogenous USP9X in HEK 293T cells that were transfected with FLAG-tagged XIAP or empty vector (EV) and synchronized in
mitosis using nocodazole or left untreated.
D Co-immunoprecipitation of XIAP and endogenous USP9X in HEK 293T cells that were treated as in (C), but with additional transfection of the FLAG-tagged XIAP single
amino acid mutants G188R and G188E. Only mitotic samples are shown. The asterisk denotes ubiquitylated forms of XIAP.
E In vivo ubiquitylation of XIAP in HeLa cells that were infected with the indicated expression constructs carrying FLAG-tagged XIAP and transfected with siRNA
oligonucleotides as specified. Cells were synchronized in mitosis using sequential thymidine/nocodazole treatment, as indicated. Subsequent to treatment with
MG132, whole-cell extracts (WCE) were prepared and ubiquitylated XIAP was isolated by anti-FLAG immunoprecipitation (IP) under denaturing conditions.
F Immunoblot analysis of NIH 3T3 cells that were transfected with expression constructs for USP9XWT or the catalytically inactive mutant USP9XC1556S. The band in the
EV control lane of the anti-V5 panel marks an unspecific band produced by the antibody.
G Immunoblot analysis of HeLa cells using antibodies to the indicated endogenous proteins that were synchronized in mitosis using thymidine/nocodazole and treated
with DMSO or the USP9X inhibitor WP1130 as indicated.
Source data are available online for this figure.
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We reasoned that USP9X deubiquitylates XIAP to regulate mitotic
survival. To investigate this possibility, we silenced USP9X expres-
sion and analyzed cell death under conditions of prolonged
taxol-induced mitotic arrest. Indeed, suppression of the USP9X–
XIAP axis increased mitotic cell death in wild-type MEFs as
evidenced by an increase of the sub-G1 fraction and a decrease of
the mitotic cell population as well as by an increase of cleaved
caspase-3 and loss of cyclin B1 expression (Fig 2A and B). Impor-
tantly, Usp9X knockdown did not induce specific loss of the mitotic
compartment in Xiap/ cells, indicating that USP9X promotes
mitotic survival directly via stabilization of XIAP (Fig 2B). Of further
notice, Xiap/, but not cIap2/, cells demonstrate an increased
overall sensitivity toward taxol exposure in the control setting, thus
further emphasizing a role for XIAP in preventing mitotic apoptosis
(Fig 2A and B). A previous study suggested MCL1 as a cell cycle-
independent substrate of USP9X (Schwickart et al, 2010). In addi-
tion, MCL1 has been shown to be ubiquitylated and degraded via
APC/CCdc20 and SCFFbxw7 upon onset of mitosis (Harley et al, 2010;
Inuzuka et al, 2011; Wertz et al, 2011). We therefore investigated
the effect of Usp9X knockdown in Mcl1/ MEFs to rule out the
possibility that USP9X mediates its mitosis-specific effects by stabi-
lizing MCL1. Indeed, knockdown of Usp9X increased mitotic cell
death in Mcl1/ cells to a similar extent as in WT MEFs, thus indi-
cating independence of MCL1 (Fig 2A and B). The elevated baseline
apoptosis observed in Mcl1/ cells is likely attributable to elevated
spontaneous apoptosis and higher sensitivity to infection proce-
dures, which have been reported for these cells (Opferman et al,
2005). In line with these observations, neither USP9X overexpres-
sion nor USP9X knockdown affected expression levels of MCL1 in
mitotically arrested cells (Figs 1G and 2A). Finally, we investigated
the impact of forced USP9X and XIAP expression as well as XIAP
silencing on mitotic survival. In accordance with the results above,
overexpression of either USP9X or XIAP protected cells from apopto-
sis, as visualized by a decrease of caspase-3 cleavage (Fig 2C and D)
and the reduction of the apoptotic index (Fig 2E). By contrast, this
effect was not observed upon expression of the USP9X binding-defi-
cient XIAPG188R and XIAPG188E mutants, presumably because of their
decreased mitotic stability (Fig EV1C). Likewise, loss of XIAP
promoted cell death upon prolonged taxol-induced mitotic arrest
(Fig 2F).
Together, the above results demonstrate that USP9X confers
mitotic stability to XIAP during the activated SAC by means of inter-
action with XIAP at glycine residue 188 and subsequent specific
deubiquitylation, thereby mediating mitotic survival independent of
MCL1. Of notice, unchallenged XIAP-deficient mice are viable and
do not show any substantial histopathological abnormalities (Harlin
et al, 2001; Olayioye et al, 2005). Our results suggest that XIAP may
be of particular relevance in a cellular environment that challenges
mitotic survival.
The evasion of apoptosis is particularly pertinent to B-cell
lymphomagenesis, where in the cells of origin, DNA double-strand
breaks are a physiological process during the formation and revision
of antigen receptors, requiring efficient means to eliminate cells
with persistent DNA damage. In addition, agents like vinca alkaloids
that target the mitotic checkpoint are key components of current
first-line lymphoma treatment protocols (Shaffer et al, 2012; Wilson,
2013). We therefore investigated whether the USP9X–XIAP circuit is
involved in the pathophysiology and therapy resistance of B-cell
lymphomas. This effort was further fostered by different lymphoma
aCGH and NGS studies that suggest overexpression and copy
number gains of USP9X in human diffuse large B-cell lymphoma
(DLBCL) (Bea et al, 2005; Morin et al, 2013).
First, we investigated the role of USP9X-mediated stabilization of
XIAP in the context of B-cell lymphoma maintenance in vivo. For
these studies, we chose a syngeneic approach using primary El-Myc
B-cell lymphoma-derived cells. The El-Myc mouse model is well
established to study alterations in apoptotic pathways that drive
B-cell lymphoma development and maintenance (Adams et al, 1985;
Vaux et al, 1988; Eischen et al, 1999). Given the short latency of
this approach, we chose to silence either Usp9X or Xiap (Fig 3A),
which would be predicted to delay disease onset. Indeed, lymphoma
onset was substantially delayed in mice receiving either Usp9X- or
Xiap-silenced cells (Fig 3B and C), in line with an in vitro analysis
of the respective cells (Appendix Fig S2A). At necropsy, lesions
were confirmed to be B-cell lymphoma, and increased apoptosis as
well as reduced infiltration of lymph nodes and bone marrow was
present in both Usp9X- and Xiap-silenced specimens (Fig 3D and E,
and Appendix Fig S2B and C). In a complimentary approach using
PET analysis, we found significantly reduced tumor burden of mice
receiving Usp9X- or Xiap-silenced cells 2 weeks after lymphoma cell
injection (Fig 3F). Of notice, simultaneous knockdown of Usp9X
and Xiap did not increase survival as compared to the single Xiap
knockdown, indicating that USP9X functions via XIAP to promote
lymphoma survival and growth in this model (Appendix Fig S2D
and E). Importantly, response to vincristine treatment was substan-
tially increased in mice receiving Usp9X or Xiap knockdown cells
(Fig 3G and H, and Appendix Fig S2F). These data suggest that
USP9X-mediated stabilization of XIAP promotes growth, survival,
and resistance to spindle poisons in B-cell lymphoma.
We next investigated the role of the USP9X–XIAP axis in human
DLBCL cell lines.
To this end, we first specified human DLBCL cell lines with either
low (SuDHL 4, SuDHL 6, Oci-Ly 3) or high (RIVA, HT, Oci-Ly 10)
USP9X expression and found associated high expression of XIAP
(Fig 4A). Notably, RIVA, HT, and Oci-Ly 10 cells demonstrate
increased resistance toward taxol treatment (Fig 4B). To investigate
a direct functional involvement of USP9X, we silenced USP9X in
these cells and treated with either taxol or doxorubicin, which typi-
cally induces G2/M arrest in tumor cells via activation of the DNA
damage response. Indeed, USP9X knockdown resolved resistance to
taxol or doxorubicin in USP9X/XIAP high-expressing cells (HT,
RIVA) as demonstrated by caspase-3 cleavage, while the USP9X/
XIAP low-expressing cell lines SuDHL 4 and SuDHL 6 were not
significantly affected (Figs 4C and EV3A). Similar results were
observed in a complementary approach using the USP9X inhibitor
WP1130 in SuDHL 6, Oci-Ly 3, HT, and Oci-Ly 10 cells treated with
taxol (Kapuria et al, 2010; Wang et al, 2014; Figs 4D and EV3B).
X-linked inhibitor of apoptosis protein is naturally inhibited by
SMAC (second mitochondria-derived activator of caspases)/DIABLO
(direct inhibitor of apoptosis-binding protein with low isoelectric
point) binding, which results in the release and activation of
caspase-9 (Du et al, 2000). Small-molecule inhibitors mimicking this
effect, that is, SMAC mimetics, have shown potent apoptosis-
inducing activity in cell culture, animal models, and early clinical trials
(Fulda & Vucic, 2012). We therefore treated DLBCL cells with the
SMAC mimetic BV6 and/or taxol. Indeed, we observed significant
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Figure 2. USP9X stabilizes XIAP to antagonize mitotic cell death independent of MCL1.
A Immunoblot analysis of WT, Xiap/, Mcl1/, or cIap2/ mouse embryonic fibroblasts that were lentivirally infected with shRNA constructs directed against a non-
relevant mRNA (Ctrl) or against Usp9X mRNA and treated with taxol as specified.
B Two-dimensional cell cycle analysis (BrdU/PI) of cells described in (A). Sub-G1 and G2/M fractions of cells were quantified and averaged with two additional,
independent experiments (n = 3,  SD; WT: **P = 0.0016; ***P = 0.0004; Mcl1/: ***P = 0.0003; **P = 0.0017; cIap2/: **P = 0.0043, Student’s t-test). Black bars
exemplify shRNA Ctrl and white bars shRNA Usp9X samples.
C Immunoblot analysis of HeLa cells transfected with a FLAG-tagged USP9X expression construct or empty vector (EV) and treated with taxol for the indicated times.
D Immunoblot analysis of HeLa cells transfected with a FLAG-tagged XIAP expression construct or empty vector and treated as in (C).
E Two-dimensional cell cycle analysis (BrdU/PI) of cells described in (C) and (D). Apoptotic indices represent ratios of sub-G1 to G1/S cells and are shown for analyses at
the indicated time points (n = 3,  SD). **P = 0.0020; ***P = 0.0004; Student’s t-test.
F Immunoblot analysis of HeLa cells that were transfected with siRNA oligonucleotides directed against a non-relevant mRNA (Ctrl) or against Xiap mRNA and treated
with taxol as specified.
Source data are available online for this figure.
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Figure 3. USP9X and XIAP promote lymphoma growth and resistance to spindle poisons in vivo.
A Immunoblot analysis of sorted El-Myc lymphoma cells that were retrovirally transduced with the indicated IRES-GFP shRNA constructs.
B Kaplan–Meier survival curves of mice that were injected intravenously with syngeneic El-Myc lymphoma cells transduced with the indicated shRNA constructs as
described in (A). Prior to injection, cells were sorted for viability (propidium iodide negative) and GFP positivity (sh_Ctrl, black, n = 6; sh_USP9X, gray, n = 5).
*P = 0.0293; Mantel–Cox test.
C Kaplan–Meier survival curves of mice that were injected with syngeneic El-Myc lymphoma cells transduced with the indicated shRNA constructs as described in (A)
and treated as in (B) (sh_Ctrl, black, n = 6; sh_XIAP, gray, n = 6). **P = 0.0020; Mantel–Cox test.
D Histopathology of representative lymph nodes derived from mice shown in (B) to visualize histomorphology by hematoxylin/eosin (H&E), B-cell origin (B220), and
spontaneous apoptosis (cleaved caspase-3) in situ. Scale bars denote 50 lm and 20 lm for insets.
E Histopathology of representative lymph nodes derived from mice shown in (C) which were stained as described in (D). Scale bars denote 50 lm and 20 lm for insets.
F Mean tumor burden in animals injected with El-Myc lymphoma cells modified as in (B) and (C), 15 days after injection, assessed by PET imaging (four animals per
group) ( SD). **P = 0.0025; ***P = 0.0003, Student’s t-test.
G Representative PET images of animals, injected with El-Myc lymphoma cells modified as in (B) and (C), 15 days after injection (pre-treatment) and 3 days following
intraperitoneal vincristine administration (post-treatment). Bone marrow infiltration, representative for systemic lymphoma manifestation, is indicated by a blue
asterisk.
H Mean change in standardized 18FDG uptake of ROI between pre- and post-treatment imaging corrected for initial tumor burden (sh_Ctrl, black, n = 6; sh_Usp9X,
white, n = 8; sh_Xiap, gray, n = 8). Within the sh_Usp9X and sh_Xiap groups, all animals lived up to control imaging, while two of eight animals of the sh_Ctrl group
had to be sacrificed prematurely because they had reached the predefined criteria of maximum tumor burden. These animals had to be excluded from final analysis,
suggesting an underestimation of the actual effect. Data were obtained from two independent experiments ( SD). ****P < 0.0001; *P = 0.0167, Student’s t-test
Source data are available online for this figure.
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potentiation of taxol-induced cell death in USP9X/XIAP high/taxol-
insensitive (HT, Oci-Ly 10, RIVA) cells, while this effect was not
present in USP9X/XIAP low/taxol-sensitive (SuDHL 4, SuDHL 6,
Oci-Ly 3) cells (Figs 4E and EV3C). SMAC mimetics have been
shown to induce degradation of cIAP1/2 (Li et al, 2004;
Varfolomeev et al, 2007; Vince et al, 2007). To rule out the possibil-
ity that increased sensitivity of USP9X/XIAP high-expressing cells to
BV6 results from increased cIAP1/2 degradation, we analyzed
cIAP1/2 levels in BV6-treated SuDHL 6 and HT cells. Indeed,
USP9X/XIAP high-expressing HT cells demonstrated only marginal
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Figure 4. USP9X is overexpressed in DLBCL to promote survival and resistance to anti-tubulin chemotherapeutics via mitotic stabilization of XIAP.
A Immunoblot analyses of different human DLBCL lines using antibodies to the indicated proteins.
B FACS analysis (propidium iodide, PI) of USP9X high- and low-expressing DLBCL cells shown in (A) to determine cell survival. Cells were treated with taxol and
collected at the specified time points. PI-negative cells are indicated relative to time point 0 (n = 3,  SD).
C Immunoblot analyses of the indicated DLBCL cell lines that were lentivirally transduced with IRES-GFP shRNA constructs against USP9X or a non-relevant mRNA,
FACS sorted for GFP+ PI cells and exposed to taxol for the indicated periods of time. The quantification of cleaved caspase-3 (CC3) at the 24 h post-taxol treatment
time point from four independent experiments is quantified in the graph on the right side and normalized to control shRNA ( SD). **P = 0.0099, Student’s t-test.
D Immunoblot analyses of the indicated DLBCL cell lines that were exposed to taxol for the indicated periods of time. Three hours before collecting, WP1130 at a
concentration of 5 lM or DMSO was added as specified.
E FACS analysis (propidium iodide (PI) uptake) of DLBCL cell lines treated with taxol and/or the SMAC mimetic BV6 as indicated. Results displayed are from three
independent experiments (n = 3,  SD). ***P = 0.00085; **P = 0.00529; Student’s t-test.
F Collective assessment of USP9X and XIAP expression determined by immunohistochemistry in tissue microarrays (TMA) derived from a patient cohort representing
121 evaluable human CD20+ aggressive B-cell lymphomas. High USP9X expression was identified in 37 cases (31%) and significantly correlated with high XIAP
expression levels (**P = 0.004; Student’s t-test).
G Expression data derived from (E) were correlated with clinical follow-up. Within a cohort of 58 patients receiving vincristine-containing chemotherapy (CHOP regimen:
cyclophosphamide, doxorubicin, vincristine, prednisone) without the addition of the anti-CD20 antibody rituximab (left panel), overexpression of USP9X and XIAP
(n = 14, straight line) was associated with a significantly shortened event-free survival (EFS) as compared to all remaining patients (n = 44, dotted line) (*P = 0.050;
log-rank test). Within a cohort of 63 patients receiving the CHOP regimen with the addition of the anti-CD20 antibody rituximab, overexpression of USP9X and XIAP
(n = 14, straight line) was not associated with a shortened event-free survival (EFS) as compared to all remaining patients (n = 49, dotted line) (P = 0.454).
Source data are available online for this figure.
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changes of cIAP1/2, in explicit contrast to USP9X/XIAP low-expres-
sing SuDHL 6 cells, while XIAP was readily destabilized (Fig EV3D).
These findings further underscore a role of XIAP as the relevant
USP9X substrate for mitotic survival in B-cell lymphoma.
To further extend our studies on the role of the USP9X–XIAP axis
in aggressive human B-cell lymphoma, we analyzed USP9X/XIAP
expression by immune histochemistry (IHC) in tissue microarrays
(TMAs) assembled from a cohort of 121 human CD20+ aggressive
B-cell lymphoma samples. These specimens were derived from the
RICOVER-60 trial of the German High Grade Non-Hodgkin’s
Lymphoma study Group (DSHNHL) and shown to be representative
of the full study population (Appendix Table S1). In the RICOVER-
60 trial, patients were randomized to receive six or eight cycles of a
chemotherapy regimen consisting of cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (CHOP) alone or in combination
with the CD20-specific antibody rituximab (Pfreundschuh et al,
2008). Indeed, IHC analyses revealed high expression of USP9X in
37 patients (31%), which significantly correlated with high XIAP
expression (P = 0.004) (Fig 4F). We further evaluated whether high
USP9X/XIAP expression correlates with clinical outcome in the
patient cohort indicated above. When treated with CHOP without
rituximab (n = 58), patients with USP9X/XIAP overexpression had
a significantly lower 2-year event-free survival [36% (95% CI
9–64%)] in a univariate analysis compared to all other patients
[71% (95% CI 57–84%; *P = 0.050; Fig 4G)]. By contrast, no signif-
icant difference was observed between the two groups when treated
with CHOP and the anti-CD20 antibody rituximab [2-year event-free
survival of 67% (95%-CI 43–94%) vs. 63% (95%-CI 50–77%) for
all other patients (P = 0.454)] (Fig 4G). While rituximab’s mecha-
nism of action is still not fully understood, a large body of evidence
suggests complement-mediated cytotoxicity (CMC) and antibody-
dependent cellular cytotoxicity (ADCC) as major means, rather than
checkpoint-induced apoptosis (Weiner, 2010).
In this analysis, USP9X/XIAP double high cases were compared
to the remaining cases (including cases with low USP9X and high
XIAP) because these cases reflect the constellation where elevated
XIAP is predicted to result from mitotic USP9X-mediated stabiliza-
tion of XIAP. Other USP9X-independent causes of elevated XIAP
levels likely exist, which would however not reflect the situation in
which DLBCL cells depend on the mitotic activity of the USP9X–
XIAP axis. Likewise, elevated USP9X expression without concomi-
tant XIAP stabilization would not reflect mitosis-specific activation
of this new mechanism. This observation thus further argues for a
specific role of the USP9X–XIAP axis in mediating resistance against
checkpoint activating agents and spindle poisons.
Diffuse large B-cell lymphoma can be categorized into three
subtypes termed germinal-center B-cell-like (GCB) DLBCL, activated
B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma
(PMBL), according to their gene expression profiles, which depend
on different oncogenic pathways (Frick et al, 2011). The ABC
subtype has been associated with unfavorable prognosis and
increased resistance to standard treatment strategies (Frick et al,
2011). We therefore evaluated a large DLBCL gene profiling dataset
with regard to USP9X expression in different subtypes (Lenz et al,
2008). This analysis however did not reveal a significant difference
between USP9X overexpression in the ABC- or GCB-type DLBCL
(Appendix Fig S3), in line with our respective analysis in DLBCL cell
lines, which also did not detect a specific pattern of USP9X
expression (ABC-type: RIVA, Oci-Ly 10, Oci-Ly 3; GCB-type: HT,
SuDHL 4, SuDHL 6). We therefore suggest that USP9X/XIAP aberra-
tions are not linked to either DLBCL subtype.
Together, our analyses in patient samples identify overexpres-
sion of USP9X/XIAP in a significant number of patients with CD20+
aggressive B-cell lymphoma and provide initial evidence that over-
expression of USP9X/XIAP may serve as a prognostic marker in
patients treated with DNA damaging agents and spindle poisons to
define a subgroup of high risk and chemotherapy refractory
patients, independent of the ABC/GCB classification. These insights
may mark a framework from which to further investigate therapeu-
tic approaches targeting USP9X and XIAP in patients with CD20+
aggressive B-cell lymphoma that display high USP9X/XIAP expres-
sion levels or spindle poison refractory disease. Our data further
suggest that the addition of SMAC mimetics, which are currently
under evaluation in early clinical trials, to spindle poison-containing
chemotherapy regimens may be such an approach that warrants
further investigation.
Materials and Methods
Cell culture and drug treatments
HeLa, Cos7, NIH 3T3, and HEK 293T were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
FBS (HEK 293T: 10% BS) and 1% penicillin/streptomycin (P/S),
and Phoenix Eco cells were kept in the same medium without
P/S. Mouse embryonic fibroblasts (MEFs) were maintained in
DMEM containing 20% FBS, 1% nonessential amino acids, and
1% P/S. Mcl-1/ MEF, Xiap/ MEF, and cIap2/ MEF were
obtained by a material transfer agreement from the Walter and
Eliza Hall Institute, Melbourne, Australia. The DLBCL lines HT,
RIVA, SuDHL 4, and SuDHL 6 were cultured in RPMI-1640 with
20% FBS and 1% P/S Oci-Ly 3 and Oci-Ly 10 in IMDM with
20% FBS, 1% P/S, and 0.1% b-mercaptoethanol. El-Myc cells
were cultured in RPMI-1640 medium supplemented with FBS
10%, nonessential amino acids 1%, b-mercaptoethanol 0.1%, and
P/S 1%. Where indicated, the following drugs were used:
MG132 (10 lM), thymidine 2 mM, nocodazole 400 ng/ml, CHX
(100 lg/ml), paclitaxel (500 nM), WP1130 (10 nM unless other-
wise specified), doxorubicin (1 lM), RO-3306 (9 lM). For
synchronization in mitosis, HeLa cells were treated with thymi-
dine, if applicable 24 h after siRNA transfection. Twenty-four
hours later, thymidine was washed off and either nocodazole was
added for another 12 h or RO-3306 was added for 16 h and then
washed off, and cells were collected one hour later. All cells
tested mycoplasma negative by a PCR detection method.
Biochemical methods
Extract preparation, immunoprecipitation, and immunoblotting
have previously been described (Bassermann et al, 2008; Fernandez-
Saiz et al, 2013; Baumann et al, 2014). Cell lysis was performed in
buffer containing glycerol 5%, Tris–HCl pH 7.5 50 mM, NaCl
250 mM, EDTA 1 mM, NP40 0.1%, MgCl2 5 mM, and protease inhi-
bitors (PIN, TPCK, TLCK, NaVa, DTT, glycerol-bisphosphate). Lysis
buffer for immunoprecipitation experiments contained Tris–HCl
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50 mM, NaCl 150 mM, EDTA 1 mM, Triton X-100 1%, and protease
inhibitors. After immunoprecipitation, beads were washed once in
lysis buffer and three times in low salt buffer (Tris–HCl pH 7.5
50 mM, NaCl 100 mM, and MgCl2 50 mM). For assessment of DUB
activity, HeLa cells were synchronized in S phase and released as
described above. At the given time points, cells were harvested and
lysed in DUB activity lysis buffer (Tris–HCl pH 7.4 50 mM, MgCl2
5 mM, sucrose 250 mM, DTT 1 mM, ATP 2 mM) for 20 min.
Subsequently, equal amounts of total protein were incubated with
human recombinant HA-ubiquitin-vinyl sulfone (Boston Biochem, #
U-212) at a concentration of 5 lM or solvent at 37°C for 30 min
and vortexed every 10 min. Thereafter, SDS was added to 1%
samples boiled at 95°C for 5 min and then incubated at room
temperature for another 5 min. Thereafter, HA immunoprecipitation
was performed. Protein in vitro translations and GST protein
purifications were essentially performed as described previously
(Bassermann et al, 2008; Fernandez-Saiz et al, 2013; Baumann
et al, 2014).
Antibodies
The following antibodies were used: beta-actin (1:10,000, mouse),
BIRC8 (mouse, Abnova # H00112401-B01), cIAP1/2, cleaved
caspase-3-5A1E (1:300, rabbit, Cell Signaling #9664), CUL1 (1:500,
mouse, Invitrogen #32-2400), cyclin A (1:1,000, mouse, Santa Cruz
#sc-751), cyclin B1 (1:1,000, mouse, Cell Signaling #4138), cyclin E
(1:1,000, mouse, kind gift of M. Pagano), FLAG (1:1,000, rabbit,
Sigma #F7425), FLAG-M2 (1:1,000, mouse, Sigma #F3165), HA-
16B12 (1:2,000, mouse, Covance #MMS-101P), human MCL1
(1:500, rabbit, BD Pharmingen #554103), murine MCL1 (1:1,000,
rabbit, A&D Serotec AHP1249), ML-IAP (mouse, Santa Cruz
#sc-71592), NIAP (rabbit, Abcam #ab25968), PARP1/2 (1:1,000,
rabbit, Santa Cruz #sc-7150), pHH3 (S10) (1:300, rabbit, Cell Signal-
ing #9701), PLK1 (1:500, rabbit, Invitrogen #33-1700), survivin
(1:3,000, rabbit, R&D Systems #AF886), USP7 (rabbit, Bethyl Lab.
#A300-033A), USP9X (1:4,000, rabbit, Bethyl Laboratories #A301-
351A), USP10 (rabbit, Bethyl Lab. #A300-900A), USP24 (Proteintech
Europe, #13126-1-AP), USP28 (rabbit, Bethyl Lab. #A300-898A), V5
(1:1,000, rabbit, Sigma #V8137), XIAP (1:1,000, mouse, BD Bio-
sciences #610716), XIAP (1:1,000, rabbit, Cell Signaling #2042), and
XIAP (1:1,000, R&D Systems #AF8221).
Immunofluorescence
For immunofluorescence microscopy, cells were grown on cover
slips prior to fixation in ice-cold methanol at 20°C for 10 min.
Primary antibodies were used as outlined above. Secondary antibod-
ies (Alexa Fluor 488 rabbit and Alexa Flour 594 goat, Life Technolo-
gies) were used at a dilution of 1:1,000. Antibodies were diluted in
IF Buffer (0.5% Tween-20 in PBS) and fixed cells mounted with
ProLong(R) Gold antifade reagent with DAPI (Life Technologies).
Images were taken using the laser-scanning confocal microscope
FluoView FV10i (Olympus).
Transient transfections and lentiviral DNA transfer
Transient transfection was performed using CaCl2 as before
(Bassermann et al, 2008) and Lipofectamine 2000© according to the
manufacturer’s description. For lentiviral shRNA transfer into
mouse embryonic fibroblasts, Phoenix Eco cell-derived media were
applied in four spin infections with Polybrene 8 lg/ml.
Plasmids, shRNA, and siRNAs
USP9X and XIAP siRNAs were obtained from Thermo Scientific
Dharmacon (Cat No. J-006099-09; Cat No. L-004098-00), and
siRNA transfection was performed using HiPerFect© Transfection
Reagent (Qiagen). shRNAs against Xiap in plko-based vectors were
a kind gift from L. Nilsson. shRNAs directed against murine Usp9X
targeted the following 21mer sequence: 50-GAT GAG GAA CCT GCA
TTT CCA-30.
Cell cycle analyses
For BrdU incorporation and DNA content analysis, cells were pulsed
with 10 lM BrdU (BD Biosciences) for 120 min and stained accord-
ing to a standard protocol thereafter. Two-dimensional flow cytome-
try was performed to detect fluorescein and PI. To quantify cell
cycle distribution, the FlowJo software (Tree Star Inc, Stanford) was
applied.
Studies in mice
El-Myc lymphoma cells were infected with lentiviral IRES-GFP
shRNA constructs directed against a non-relevant mRNA or against
USP9X mRNA or XIAP mRNA together with IRES-linked GFP, sorted
48 h thereafter, and injected into syngeneic C57BL (Harlan)
recipient mice (5 × 104 cells per mouse). Equally housed, fed, and
bred female mice of same size and age (10 weeks) were thereby
randomly distributed into experimental groups. Mice were
examined weekly by lymph node palpation. Disease state was
defined by the presence of palpable lymph nodes. Time point of
sacrifice was determined by an independent member of the mouse
facility with no insight into experimental design. To assess cell
immunophenotype and GFP content, single-cell suspensions were
obtained by passing lymph nodes and bone marrow through 70-lm
cell strainers. In preparation for FACS and immunoblotting, erythro-
cytes were lysed using buffer containing NH4Cl 0.15 M, HEPES
0.02 M, and EDTA 0.1 M. Samples for immunohistochemistry (IHC)
were fixed in 5% PFA. Survival data in each approach were
analyzed using the Kaplan–Meier method, applying the log-rank
(Mantel–Cox) test for statistical significance. Animals were censored
from analyses when sacrificed for non-tumor reasons. For the
survival and tumor growth studies, a group size of at least five
animals per condition was chosen, which allowed the detection of
twofold differences in survival with a power of 0.89, assuming a
two-sided test with a significance threshold a of 0.05 and a standard
deviation of less than 50% of the mean.
For treatment experiments, the mice of each group, regardless of
clinical tumor signs, underwent PET analysis at day 15 after injec-
tion of El-Myc lymphoma cells. Hence, they were injected with
vincristine 4 lg intraperitoneally and re-imaged 3 days thereafter
(day 18).
Experiments were performed in accordance with the local ethical
guidelines and approved by the responsible regional authorities
(Regierung von Oberbayern).
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PET data analysis
Analysis was performed using the Inveon Research workplace to
semiquantitatively assess the accumulation of tracer in the tumor.
Three-dimensional regions of interest (ROIs) were drawn manually
around lesions, and a threshold algorithm (50% maximum intensity –
minimum intensity) was applied to each ROI to obtain an intensity
value from the area with the highest tumor activity. Mean values
were taken from the lesions, and the same lesions in each mouse
were analyzed pre- and post-treatment.
Background activity was determined by establishing two identi-
cally sized 3D ROIs in the spinal muscles below the kidneys.
For evaluation of tumor response to vincristine, mean change in
18FDG uptake was assessed and corrected for tumor burden at the
time of treatment initiation.
Immunohistochemistry and tumor samples
For immunohistochemistry, tissue sections were deparaffinized.
Antigen retrieval was carried out by pressure cooking in citrate buffer
(pH 6 or pH 9) for 10 min. USP9X or XIAP was detected after an over-
night incubation at 4°C by the DAKO REAL Detection Kit (DAKO)
according to the manufacturer’s protocol. Immunohistochemical data
were interpreted by a certified pathologist blinded to clinicopatholog-
ical data. Slides were evaluated using the Axioplan 2 microscope
(Zeiss, Goettingen, Germany). A semiquantitative score for was used
to evaluate protein expression as follows: score 0: no expression,
score 1: expression in < 10% of tumor cells, score 2: expression in
> 10% of tumor cells, score 3: expression in > 50% of tumor cells.
Tumor samples showing scores 0–1 were called USP9X/XIAP low,
and samples exhibiting scores 2–3 were summarized as USP9X/XIAP
high. All human specimens were processed with informed consent in
compliance with the institutional review board at the Faculty of
Medicine of the Technical University of Munich and conformed to
the principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report.
Normalization and quantification of protein levels
Protein concentrations of whole-cell extracts (WCE) were deter-
mined using a Bio-Rad DC protein assay (Lowry assay). For each
experiment, equal amounts of WCE were separated by SDS–PAGE
and analyzed by immunoblotting. Equal protein levels in each lane
were confirmed by Ponceau S staining of the membrane and by
immunoblotting proteins whose levels are typically not regulated
in response to apoptosis or cell cycle progression (e.g., CUL1,
b-actin).
Statistical analyses
An objective was to analyze the association of USP9X–XIAP overex-
pression with event-free survival (EFS) in elderly patients with
CD20+ aggressive B-cell lymphoma, according to primary histology.
EFS was defined as time from randomization to disease progression,
start of salvage treatment, additional (unplanned) treatments,
relapse, or death from any cause.
The association of USP9X–XIAP overexpression and outcome
was tested by the log-rank test and graphically displayed via
Kaplan–Meier curves. Two-year rates with 95% confidence intervals
and P-values are presented. For comparison of patient characteris-
tics for the groups with and without TMA material, Pearson’s chi-
square tests were performed. For comparison of the median age,
Mann–Whitney U-test was used. A statistically significant difference
was assumed for P ≤ 0.05. Statistical analyses were done with SPSS
statistics version 20.
Other statistical analysis of results was performed by log-rank
(Mantel–Cox) test, Student’s t-test, or one-way ANOVA, as specified
in the individual figure legends according to the assumptions of the
test using GraphPad Prism software. The bars shown represent the
mean  standard deviation (SD). Murine outcome data were visual-
ized by Kaplan–Meier curves, and survival analyses were performed
using a log-rank test. The P-values are presented in figure legends
where a statistically significant difference was found. *P < 0.05;
**P < 0.01; ***P < 0.001.
Expanded View for this article is available online.
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The paper explained
Problem
Diffuse large B-cell lymphoma (DLBCL) is the most common type of
malignant lymphoma in adults, making up approximately 30% to 35%
of all cases. While the majority of DLBCL patients respond well to
initial chemotherapy, about half of the responders eventually relapse
and about 10% are refractory to initial treatment. Factors predicting
response to chemotherapy are not well characterized.
Results
We here identify USP9X as the deubiquitylase which mediates mito-
sis-specific stabilization of the anti-apoptotic protein XIAP. We show
that upregulation of USP9X and consequently of XIAP promote mitotic
survival and increased resistance to mitotic spindle poisons in diffuse
large B-cell lymphoma. Inactivation of both proteins sensitizes DLBCL
cells to spindle poison-induced apoptosis. Furthermore, patients with
high USP9X/XIAP expression demonstrate significantly reduced event-
free survival after chemotherapeutic treatment.
Impact
Overexpression of USP9X and XIAP is identified as a predictive
biomarker for chemotherapy resistance in aggressive B-cell lymphoma.
Targeting of USP9X or XIAP in USP9X/XIAP-overexpressing and/or
chemotherapy refractory tumors may be a promising approach to
improve survival of DLBCL patients.
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